Processing...
All Trials
Search
Search
There are 1652 active trials in our database.
Click on a trial to see more information.
1652 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Enrolls adults with progressive metastatic castration-resistant prostate adenocarcinoma after at least one prior novel androgen receptor pathway inhibitor, requiring PSMA-positive disease on PSMA PET (with RECIST-measurable disease or evaluable disease with PSA ≥1 ng/mL) and no CNS metastases. Patients undergo leukapheresis and receive a single IV infusion of AB-3028, an autologous logic-gated engineered T-cell therapy designed to activate only with PSMA plus a second priming antigen to improve tumor selectivity and limit on-target/off-tumor toxicity.
ClinicalTrials.gov ID: NCT07285694
TrialFetch AI summary: Adults with advanced/metastatic adrenocortical carcinoma or metastatic castration-resistant prostate cancer (ECOG 0–1; ECOG 2 allowed if due to cancer pain), with the mCRPC cohort requiring prior androgen receptor pathway inhibitor exposure and at least one prior chemotherapy line or ineligibility/refusal, receive oral DS9051b tablet monotherapy. This dose-escalation study is primarily assessing safety/DLTs and establishing the recommended expansion dose while looking for preliminary antitumor activity; DS9051b’s target/mechanism has not been publicly specified.
ClinicalTrials.gov ID: NCT07189403
TrialFetch AI summary: For adults (≥18) with relapsed/refractory, measurable soft tissue sarcoma after ≥1 prior systemic regimen (ECOG 0–1) whose tumors are FAP-PET–positive, this study treats with IV [Ac-225]RTX-2358, a fibroblast activation protein (FAP)–targeted actinium-225 alpha-emitting radiopharmaceutical delivering high–linear energy transfer cytotoxic radiation to the tumor microenvironment, dosed every 8 weeks for 4 cycles (up to 6 if benefiting). Patients also receive the investigational FAP-targeted PET imaging agent [Cu-64]LNTH-1363S for selection/imaging and dosimetry assessments.
ClinicalTrials.gov ID: NCT07156565
TrialFetch AI summary: Adults with RECIST-measurable advanced solid tumors (excluding primary CNS malignancies), ECOG 0–1, adequate organ function, and controlled/treated CNS disease (if present) after standard therapies are eligible. Patients receive PLT012 IV every 3 weeks, a first-in-class humanized anti-CD36 IgG4 “metabolic checkpoint” monoclonal antibody intended to block CD36-mediated lipid uptake and restore antitumor T-cell function, with treatment continuing until progression or unacceptable toxicity.
ClinicalTrials.gov ID: NCT07337525
TrialFetch AI summary: Enrolls adults with locally advanced unresectable or metastatic urothelial carcinoma who are systemic-therapy–naïve for advanced disease. Treatment is MK-3120 (SKB410; investigational Nectin-4–targeted antibody–drug conjugate delivering a topoisomerase I inhibitor payload) added to enfortumab vedotin (Nectin-4 ADC) plus pembrolizumab (anti–PD-1) as first-line therapy, continued until progression/toxicity (pembrolizumab up to 35 cycles).
ClinicalTrials.gov ID: NCT07232602
TrialFetch AI summary: Enrolls adults with locally advanced/metastatic/unresectable solid tumors harboring ERBB2 (HER2) activating alterations, NRG1 fusions, or HER2 overexpression, with expansion cohorts for ERBB2-mutant NSCLC with brain metastases and ERBB2-mutant or HER2-overexpressing breast cancer with brain metastases ± leptomeningeal disease. Patients receive oral CGT4255, an investigational EGFR-sparing selective HER2 tyrosine kinase inhibitor designed to cover multiple oncogenic HER2 mutations with CNS penetration, given at escalating/selected doses.
ClinicalTrials.gov ID: NCT07361562
TrialFetch AI summary: Adults with ECOG 0–1 locally advanced unresectable or metastatic solid tumors (including NSCLC without actionable alterations, urothelial carcinoma, gastric/GEJ cancer, and HER2-negative breast cancer) in selected treatment settings, including 2L+ NSCLC and post–enfortumab vedotin+pembrolizumab urothelial carcinoma, plus first-line metastatic NSCLC (adenocarcinoma) and urothelial cohorts. Patients receive IV ASP2998, a first-in-human TROP2-targeting antibody–drug conjugate, as monotherapy or combined with pembrolizumab and/or carboplatin, and/or with enfortumab vedotin (urothelial cohorts), in 21-day cycles until progression or toxicity.
ClinicalTrials.gov ID: NCT07287995
TrialFetch AI summary: For adults with locally advanced or metastatic breast cancer (ECOG 0–1) previously treated with standard subtype-appropriate therapy (including prior endocrine therapy + CDK4/6 inhibitor for ER+/HER2−), enrolling molecularly defined cohorts: ER+/HER2−, ER+/HER2− with FGFR1 amplification, and luminal androgen receptor–subtype TNBC (AR ≥10% by IHC), generally with measurable disease and available tumor tissue. Patients receive oral BBI-940, a first-in-human kinesin molecular degrader designed to disrupt mitotic/ecDNA segregation, as monotherapy or (in ER+/HER2− without ESR1 mutation) in combination with fulvestrant.
ClinicalTrials.gov ID: NCT07408089
TrialFetch AI summary: Adults with advanced/unresectable or metastatic solid tumors that have progressed after, are intolerant to, or lack standard systemic options (ECOG 0–1; measurable disease; excluding prior B7-H3–targeted therapy, prior topoisomerase inhibitor ADCs, significant ILD/pneumonitis, uncontrolled infection, or active/untreated CNS metastases). Patients receive SYS6043, an IV q3-week B7-H3 (CD276)–targeted antibody–drug conjugate delivering a cytotoxic payload to B7-H3–expressing tumor cells, with expansion cohorts planned in ES-SCLC, HR+/HER2− breast cancer, mCRPC, and ovarian cancer.
ClinicalTrials.gov ID: NCT07424547
TrialFetch AI summary: Enrolls adults with relapsed/refractory, locally advanced inoperable, or metastatic solid tumors (including CRPC, NSCLC/SCLC, CRC, HNSCC, ovarian/cervical/endometrial cancers, TNBC, and esophageal SCC) who have progressed after their most recent therapy and have no suitable standard option, with ECOG 0–2 and adequate organ function (measurable disease required except in CRPC; prior Lu-177–PSMA excluded for CRPC). Patients receive 177Lu-BetaBart, a lutetium-177–labeled anti–B7-H3 (CD276) monoclonal antibody delivering beta-particle radiation as systemic radioimmunotherapy in a dose-escalation/expansion design.
ClinicalTrials.gov ID: NCT07189871